DLPIC
MRTX

Davide Leone & Partners Investment Company’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Davide Leone & Partners Investment Company’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-11,117
Closed -$1.9M – 112
2021
Q1 		$1.9M Buy
11,117
+4,201
+61% +$832K 0.24% 58
2020
Q4 		$1.52M Buy
+6,916
New +$1.5M 0.16% 76

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Davide Leone & Partners Investment Company's MRTX Position: Q2 2021 in Review

Davide Leone & Partners Investment Company sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2021, closing a stake of 11,117 shares — an estimated $1.9M sold.

Davide Leone & Partners Investment Company first reported a position in MRTX in Q4 2020 and held it in 2 quarters. The position peaked at $1.9M in Q1 2021. 245 funds tracked by Wall St. Rank hold MRTX as of Q2 2021.

  • Davide Leone & Partners Investment Company reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Davide Leone & Partners Investment Company sold 11,117 Mirati Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $1.9M.
  • Davide Leone & Partners Investment Company first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Davide Leone & Partners Investment Company's Mirati Therapeutics, Inc. Common Stock position peaked at $1.9M in Q1 2021.
  • 245 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Davide Leone & Partners Investment Company's 13F filing for Q2 2021, filed 16 Aug 2021.